Home > Health A – Z > Esophagitis

Esophagitis

Inflammation of the esophagus (the tube that carries food from the mouth to the stomach).

PubMed Health Glossary
(Source: NIH - National Cancer Institute)

What works? Research summarized

Evidence reviews

Medical treatments for eosinophilic esophagitis (a chronic disease associated with increased numbers of eosinophils in the esophagus and symptoms of esophagitis)

Eosinophilic esophagitis (EE) is emerging globally as a significant cause of upper gastrointestinal disease in people with clinical symptoms of esophageal disease including a typical appearance of the esophagus and an increased number of eosinophil white blood cells when the esophagus is examined by an endoscope using high magnification.

Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 [Internet]

Proton pump inhibitors decrease secretion of gastric acid. They act by blocking the last enzyme in the system that actively transports acid from gastric parietal cells into the gastrointestinal lumen, hydrogen–potassium adenosine triphosphatase, also known as the proton pump. Omeprazole, the first drug in this class, was introduced in 1989. Since then, 4 other proton pump inhibitors have been introduced: lansoprazole (1995), rabeprazole (1999), pantoprazole (2000), and esomeprazole (2001). In 2003 omeprazole became available over-the-counter in the United States. The purpose of this review is to compare the benefits and harms of different PPIs.

Infrequent chemoradiation-induced acute esophagitis in the Asian population: a meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer

Bibliographic details: Komiya T, Palla SL, Wang F, Perez RP, Huang CH.  Infrequent chemoradiation-induced acute esophagitis in the Asian population: a meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer. Thoracic Cancer 2014; 5(6): 565-569 Available from: http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12141/abstract

See all (102)

Summaries for consumers

Medical treatments for eosinophilic esophagitis (a chronic disease associated with increased numbers of eosinophils in the esophagus and symptoms of esophagitis)

Eosinophilic esophagitis (EE) is emerging globally as a significant cause of upper gastrointestinal disease in people with clinical symptoms of esophageal disease including a typical appearance of the esophagus and an increased number of eosinophil white blood cells when the esophagus is examined by an endoscope using high magnification.

Comparing Proton Pump Inhibitors

How do proton pump inhibitors compare in gastroesophageal reflux disease (GERD)?

Early (less than 30 days after the start of chemotherapy) or late (more than 30 days after the start of chemotherapy) chest radiotherapy for patients suffering from limited small cell lung cancer

Between 7% and 8% of lung cancers are of the type known as limited‐stage small cell tumours. People with this type of cancer have a limited chance of being cured with chemotherapy and radiotherapy. It is not known when the optimum time to give chest radiotherapy is in relation to administering chemotherapy treatment. This review indicates that it is unclear whether administering chest radiotherapy within 30 days of beginning chemotherapy or later improves survival. The effect on patients' overall survival is not statistically different, although there is a possibility that the effect is in favour of early chest radiotherapy. The interpretation of the current data is difficult and further research is needed.

See all (12)

More about Esophagitis

Photo of an adult

Other terms to know:
Barrett's Esophagus, Esophagus, Inflammation

Keep up with systematic reviews on Esophagitis:

RSS

PubMed Health Blog...

read all...